29 patents
Utility
Respiratory Tract Delivery of Levodopa and Dopa Decarboxylase Inhibitor for Treatment of Parkinson's Disease
28 Sep 23
A dry pharmaceutical composition is provided that is suitable for respiratory tract delivery of levodopa and DDI for treatment of Parkinson's disease or Parkinson syndrome.
John D. Hoekman, Kelsey H. Satterly, Inna Dashevsky, Aditya R. Das, Stephen B. Shrewsbury, Gregory J. Davies, Bhavin Y. Gajera
Filed: 6 May 23
Utility
Nasal drug delivery device with detachable nozzle
19 Sep 23
A nasal drug delivery device for delivering a plume derived from a propellant and a drug compound.
Christopher William Fuller, Craig Frederick Kohring, Albert Kenneth Lavin, John D. Hoekman
Filed: 17 Dec 19
Utility
Intranasal delivery of olanzapine by precision olfactory device
12 Sep 23
Methods are provided for acute treatment of agitation, including agitation in patients with schizophrenia or bipolar disorder, comprising administering to a subject with agitation an effective dose of a dry pharmaceutical composition comprising olanzapine, wherein the dose is administered by an intranasal delivery device that provides, following intranasal administration, (a) a mean peak plasma olanzapine concentration (Cmax) of at least 30 ng/mL, with (b) a mean time to Cmax (Tmax) of olanzapine of less than 0.5 hours.
John D. Hoekman, Kelsey H. Satterly, Inna Dashevsky, Aditya R. Das
Filed: 12 Jan 22
Utility
Nasal drug delivery device
22 Aug 23
A compound delivery device for delivering a plume derived from a propellant and a drug formulation.
John D. Hoekman, Michael Hite, Alan Brunelle, Joel Relethford, Rodney J. Y. Ho
Filed: 25 Oct 19
Utility
In-line Nasal Delivery Device
3 Aug 23
A delivery device for a compound including: a housing, vial holding a compound; and a source of propellant, wherein the housing provides an inlet and an outlet for the vial, wherein the inlet is in fluid communication with the source of propellant and is directed against the compound and the outlet allows for delivery of the compound.
John D. Hoekman, Christopher Fuller, Craig Kohring
Filed: 8 Apr 23
Utility
Respiratory tract delivery of levodopa and DOPA decarboxylase inhibitor for treatment of Parkinson's disease
4 Jul 23
A dry pharmaceutical composition is provided that is suitable for respiratory tract delivery of levodopa and DDI for treatment of Parkinson's disease or Parkinson syndrome.
John D. Hoekman, Kelsey H. Satterly, Inna Dashevsky, Aditya R. Das, Stephen B. Shrewsbury, Gregory J. Davies, Bhavin Y. Gajera
Filed: 28 Feb 22
Utility
In-line Nasal Delivery Device
30 Mar 23
A deliver device for a compound including: a housing, vial holding a compound; and a source of propellant, wherein the housing provides an inlet and an outlet for the vial, wherein the inlet is in fluid communication with the source of propellant and is directed against the compound and the outlet allows for delivery of the compound.
John D. Hoekman, Christopher Fuller, Craig Kohring
Filed: 15 Jul 22
Utility
Intranasal device with dip tube
7 Feb 23
A device for delivering a compound to the olfactory region of the nasal cavity includes an actuator body and a tip configured to removably couple to the actuator body.
Craig Frederick Kohring, Christopher William Fuller
Filed: 21 Nov 18
Utility
Respiratory tract delivery of levodopa and DOPA decarboxylase inhibitor for treatment of Parkinson's Disease
6 Dec 22
A dry pharmaceutical composition is provided that is suitable for respiratory tract delivery of levodopa and DDI for treatment of Parkinson's disease or Parkinson syndrome.
John D. Hoekman, Kelsey H. Satterly, Inna Dashevsky, Aditya R. Das, Stephen B. Shrewsbury, Gregory J. Davies, Bhavin Y. Gajera
Filed: 19 Jul 19
Utility
Intranasal Device with Inlet Interface
13 Oct 22
A device for delivering a compound to the olfactory region of the nasal cavity includes an actuator body and a tip that removably couples to the actuator body.
Craig Frederick Kohring, Christopher William Fuller
Filed: 8 Jun 22
Utility
Intranasal Delivery of Levodopa Powder by Precision Olfactory Device
22 Sep 22
Methods are provided for treating OFF episodes in a patient with Parkinson's disease or a Parkinson syndrome, comprising administering to a subject with Parkinson's disease or a Parkinson syndrome experiencing an OFF episode an effective dose of a dry pharmaceutical composition comprising L-DOPA, wherein the dose is administered by an intranasal delivery device that provides, following intranasal administration, (a) a mean peak plasma levodopa concentration (Cmax) of at least 200 ng/mL, with (b) a mean time to Cmax (Tmax) of levodopa of less than or equal to 60 minutes.
John D. Hoekman, Kelsey H. Satterly, Inna Dashevsky, Aditya R. Das, Stephen B. Shrewsbury
Filed: 11 Oct 21
Utility
Respiratory Tract Delivery of Levodopa and Dopa Decarboxylase Inhibitor for Treatment of Parkinson's Disease
28 Jul 22
A dry pharmaceutical composition is provided that is suitable for respiratory tract delivery of levodopa and DDI for treatment of Parkinson's disease or Parkinson syndrome.
John D. Hoekman, Kelsey H. Satterly, Inna Dashevsky, Aditya R. Das, Stephen B. Shrewsbury, Gregory J. Davies, Bhavin Y. Gajera
Filed: 28 Feb 22
Utility
Intranasal device with inlet interface
26 Jul 22
A device for delivering a compound to the olfactory region of the nasal cavity includes an actuator body and a tip that removably couples to the actuator body.
Craig Frederick Kohring, Christopher William Fuller
Filed: 21 Nov 18
Utility
Nasal Drug Delivery Device
24 Mar 22
A nasal drug delivery device for delivering a plume derived from a propellant and a drug compound.
Christopher William FULLER, Craig Frederick KOHRING, Albert Kenneth LAVIN, John D. HOEKMAN
Filed: 17 Dec 19
Utility
Intranasal delivery of olanzapine by precision olfactory device
22 Mar 22
Methods are provided for acute treatment of agitation, including agitation in patients with schizophrenia or bipolar disorder, comprising administering to a subject with agitation an effective dose of a dry pharmaceutical composition comprising olanzapine, wherein the dose is administered by an intranasal delivery device that provides, following intranasal administration, (a) a mean peak plasma olanzapine concentration (Cmax) of at least 30 ng/mL, with (b) a mean time to Cmax (Tmax) of olanzapine of less than 0.5 hours.
John D. Hoekman, Kelsey H. Satterly, Inna Dashevsky, Aditya R. Das
Filed: 4 Jan 19
Utility
In-line nasal delivery device
8 Mar 22
A delivery device for a compound including: a housing, vial holding a compound; and a source of propellant, wherein the housing provides an inlet and an outlet for the vial, wherein the inlet is in fluid communication with the source of propellant and is directed against the in-line nasal delivery device compound and the outlet allows for delivery of the compound.
Christopher Fuller, John D. Hoekman, Craig Kohring
Filed: 9 Sep 16
Utility
Medical unit dose container
7 Dec 21
A unit dose container for the containment of an intranasal formulation for use with the POD device.
John D. Hoekman, Alan Brunelle, Craig Kohring, Christopher Fuller
Filed: 25 Nov 19
Utility
Intranasal delivery of dihydroergotamine by precision olfactory device
30 Nov 21
Methods are provided for acutely treating migraine headache with or without aura.
John D. Hoekman, Kelsey H. Satterly, Stephen B. Shrewsbury, Scott Youmans, Christopher Fuller
Filed: 2 Oct 20
Utility
Nozzles for Nasal Drug Delivery
21 Oct 21
A nozzle for use in delivering a mixture of aerosol propellant and drug formulation.
John D. Hoekman, Michael Hite, Alan Brunelle, Joel Relethford
Filed: 1 Feb 21
Utility
Repeated Administration of Dihydroergotamine for Treatment of Frequent Migraine Headaches
5 Aug 21
Methods are provided for reducing the frequency of migraine attacks in a subject who has frequent migraine headaches with or without aura.
John D. Hoekman, Kelsey H. Satterly, Stephen B. Shrewsbury, Scott Youmans, Christopher Fuller
Filed: 13 Jan 21